Visual Overview
Abstract
The corticotropin-releasing factor (CRF) system, which is involved in stress, addiction, and anxiety disorders such as depression, acts through G-protein–coupled receptors (GPCRs) known as type-1 and type-2 CRF receptors. The purpose of this review is to highlight recent advances in the interactions of CRF receptors with other GPCRs and non-GPCR proteins and their associated functional consequences. A better understanding of these interactions may generate new pharmacological alternatives for the treatment of addiction and stress-related disorders.
Footnotes
- Received April 26, 2016.
- Accepted September 8, 2016.
↵1 P.G.S. and H.E.Y. contributed equally to this work.
This work was supported by FONDECYT (Grant 1150244) and by CONICYT Ph.D. fellowships to P.G.S. and H.E.Y.
- Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement